首页> 外文期刊>Clinical and experimental ophthalmology >Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year
【24h】

Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year

机译:胶原基质植入物在小梁切除术中的疗效和安全性以及与丝裂霉素C增强小梁切除术在1年时的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: To assess the efficacy and safety of collagen matrix implant (Ologen) in phacotrabeculectomy. Design: Prospective, non-randomized, comparative study. Participants: Sixty-six Asian patients. Methods: Thirty three consecutive patients underwent phacotrabeculectomy with Ologen implant and intraocular lens implantation, and 33 subjects recruited as controls underwent surgery with mitomycin C augmentation. Main Outcome Measures: The primary outcome measure was postoperative intraocular pressure at month 12. Additional postoperative treatments, such as bleb needling, and adverse events were secondary outcomes. Results: The overall percentage reduction in intraocular pressure was 13% (95% confidence interval 6.7-19.2) in the Ologen group and 26% (95% confidence interval 14.8-37.9) in the mitomycin C group (P=0.05). At 1 year after surgery (after adjusting for baseline differences), intraocular pressure decreased by 4.2mmHg (95% confidence interval 2.8-5.6mmHg) and 5.6mmHg (95% confidence interval 4.2-7.0mmHg), respectively (P=0.16). Needling with 5-fluorouracil was required more often in the Ologen group (39% vs. 6%; P=0.003). There was similar frequency (<10%) of adverse events in both groups, and there were no complications directly related to the Ologen implant. The blebs in the mitomycin C group had greater central area (P=0.005), maximal area (P=0.01) and height (P=0.005), and were less vascular (P=0.023) than the Ologen blebs. Conclusions: At 1 year, the overall performance of Ologen in combined phacotrabeculectomy was suboptimal compared with combined surgery with mitomycin C. Eyes in the Ologen group required more frequent bleb needling procedures.
机译:背景:评估胶原基质植入物(Ologen)在白内障小梁切除术中的疗效和安全性。设计:前瞻性,非随机,比较研究。参加者:六十六名亚洲患者。方法:连续33例患者接受了Ologen植入物和人工晶状体植入术的小梁切除术,并招募了33名作为对照的受试者进行了丝裂霉素C增强手术。主要结果指标:主要结果指标是术后第12个月的眼内压。其他术后治疗方法,如起泡针刺和不良反应为次要结果。结果:Ologen组眼压总体降低百分比为13%(95%置信区间6.7-19.2),丝裂霉素C组为26%(95%置信区间14.8-37.9)(P = 0.05)。术后1年(校正基线差异后),眼压分别下降4.2mmHg(95%置信区间2.8-5.6mmHg)和5.6mmHg(95%置信区间4.2-7.0mmHg)(P = 0.16)。在Ologen组中,更经常需要使用5-氟尿嘧啶进行针刺(39%对6%; P = 0.003)。两组不良事件的发生频率相似(<10%),并且没有与Ologen植入直接相关的并发症。丝裂霉素C组的小泡比Ologen小泡具有更大的中心面积(P = 0.005),最大面积(P = 0.01)和高度(P = 0.005),并且血管少(P = 0.023)。结论:在1年时,与联合丝裂霉素C联合手术相比,在联合超声乳化小梁切除术中Ologen的总体表现欠佳。Ologen组的眼睛需要更频繁的起泡针刺程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号